|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXO7 |
Gene summary for FBXO7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXO7 | Gene ID | 25793 |
| Gene name | F-box protein 7 | |
| Gene Alias | FBX | |
| Cytomap | 22q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | Q9Y3I1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25793 | FBXO7 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.59e-05 | 4.91e-01 | -0.0811 |
| 25793 | FBXO7 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.22e-06 | 3.35e-01 | -0.1954 |
| 25793 | FBXO7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.43e-08 | 4.83e-01 | -0.059 |
| 25793 | FBXO7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.08e-03 | 2.33e-01 | 0.0674 |
| 25793 | FBXO7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.33e-12 | 4.99e-01 | 0.294 |
| 25793 | FBXO7 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 2.24e-02 | 8.03e-01 | 0.3487 |
| 25793 | FBXO7 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.95e-11 | 5.32e-01 | 0.3859 |
| 25793 | FBXO7 | A015-C-203 | Human | Colorectum | FAP | 1.40e-05 | -1.19e-01 | -0.1294 |
| 25793 | FBXO7 | A001-C-108 | Human | Colorectum | FAP | 2.98e-02 | -1.07e-01 | -0.0272 |
| 25793 | FBXO7 | A002-C-205 | Human | Colorectum | FAP | 6.28e-03 | -1.40e-01 | -0.1236 |
| 25793 | FBXO7 | A002-C-114 | Human | Colorectum | FAP | 8.55e-03 | -1.84e-01 | -0.1561 |
| 25793 | FBXO7 | A015-C-104 | Human | Colorectum | FAP | 2.30e-04 | -8.95e-02 | -0.1899 |
| 25793 | FBXO7 | A002-C-116 | Human | Colorectum | FAP | 6.96e-05 | -8.61e-02 | -0.0452 |
| 25793 | FBXO7 | F034 | Human | Colorectum | FAP | 1.35e-02 | -7.51e-02 | -0.0665 |
| 25793 | FBXO7 | LZE4T | Human | Esophagus | ESCC | 1.29e-18 | 3.11e-01 | 0.0811 |
| 25793 | FBXO7 | LZE5T | Human | Esophagus | ESCC | 2.51e-05 | 2.05e-01 | 0.0514 |
| 25793 | FBXO7 | LZE7T | Human | Esophagus | ESCC | 4.73e-10 | 7.54e-01 | 0.0667 |
| 25793 | FBXO7 | LZE8T | Human | Esophagus | ESCC | 5.66e-12 | 2.17e-01 | 0.067 |
| 25793 | FBXO7 | LZE22T | Human | Esophagus | ESCC | 3.46e-02 | 3.49e-01 | 0.068 |
| 25793 | FBXO7 | LZE24T | Human | Esophagus | ESCC | 1.29e-26 | 9.28e-01 | 0.0596 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190040712 | Liver | HCC | regulation of cellular response to oxidative stress | 50/7958 | 89/18723 | 6.33e-03 | 2.58e-02 | 50 |
| GO:190320112 | Liver | HCC | regulation of oxidative stress-induced cell death | 42/7958 | 74/18723 | 9.32e-03 | 3.57e-02 | 42 |
| GO:190320311 | Liver | HCC | regulation of oxidative stress-induced neuron death | 18/7958 | 27/18723 | 9.75e-03 | 3.66e-02 | 18 |
| GO:007259418 | Oral cavity | OSCC | establishment of protein localization to organelle | 284/7305 | 422/18723 | 1.50e-32 | 1.35e-29 | 284 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:000989620 | Oral cavity | OSCC | positive regulation of catabolic process | 307/7305 | 492/18723 | 2.29e-26 | 7.64e-24 | 307 |
| GO:003133120 | Oral cavity | OSCC | positive regulation of cellular catabolic process | 273/7305 | 427/18723 | 6.39e-26 | 2.02e-23 | 273 |
| GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
| GO:000660520 | Oral cavity | OSCC | protein targeting | 204/7305 | 314/18723 | 6.78e-21 | 1.13e-18 | 204 |
| GO:003164720 | Oral cavity | OSCC | regulation of protein stability | 193/7305 | 298/18723 | 1.30e-19 | 1.95e-17 | 193 |
| GO:00447728 | Oral cavity | OSCC | mitotic cell cycle phase transition | 255/7305 | 424/18723 | 5.29e-19 | 6.98e-17 | 255 |
| GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
| GO:00073469 | Oral cavity | OSCC | regulation of mitotic cell cycle | 266/7305 | 457/18723 | 3.87e-17 | 3.41e-15 | 266 |
| GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
| GO:000683918 | Oral cavity | OSCC | mitochondrial transport | 162/7305 | 254/18723 | 8.96e-16 | 6.52e-14 | 162 |
| GO:19030088 | Oral cavity | OSCC | organelle disassembly | 85/7305 | 114/18723 | 1.15e-14 | 6.93e-13 | 85 |
| GO:007058518 | Oral cavity | OSCC | protein localization to mitochondrion | 91/7305 | 125/18723 | 1.60e-14 | 9.27e-13 | 91 |
| GO:007265518 | Oral cavity | OSCC | establishment of protein localization to mitochondrion | 88/7305 | 120/18723 | 2.10e-14 | 1.19e-12 | 88 |
| GO:005134820 | Oral cavity | OSCC | negative regulation of transferase activity | 165/7305 | 268/18723 | 5.02e-14 | 2.74e-12 | 165 |
| GO:003459920 | Oral cavity | OSCC | cellular response to oxidative stress | 173/7305 | 288/18723 | 2.90e-13 | 1.43e-11 | 173 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXO7 | SNV | Missense_Mutation | c.1042N>T | p.Asp348Tyr | p.D348Y | Q9Y3I1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| FBXO7 | SNV | Missense_Mutation | novel | c.1171N>C | p.Asp391His | p.D391H | Q9Y3I1 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| FBXO7 | SNV | Missense_Mutation | c.997N>C | p.Val333Leu | p.V333L | Q9Y3I1 | protein_coding | tolerated(0.37) | benign(0.007) | TCGA-D8-A1XR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| FBXO7 | insertion | Frame_Shift_Ins | novel | c.616_617insAAAATTT | p.Leu206GlnfsTer32 | p.L206Qfs*32 | Q9Y3I1 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| FBXO7 | SNV | Missense_Mutation | c.823N>C | p.Lys275Gln | p.K275Q | Q9Y3I1 | protein_coding | tolerated(0.12) | possibly_damaging(0.795) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FBXO7 | SNV | Missense_Mutation | rs376214763 | c.652G>A | p.Glu218Lys | p.E218K | Q9Y3I1 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXO7 | SNV | Missense_Mutation | c.713N>T | p.Tyr238Phe | p.Y238F | Q9Y3I1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| FBXO7 | SNV | Missense_Mutation | c.848N>A | p.Ser283Tyr | p.S283Y | Q9Y3I1 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| FBXO7 | SNV | Missense_Mutation | rs376455464 | c.521N>T | p.Ser174Leu | p.S174L | Q9Y3I1 | protein_coding | deleterious(0) | benign(0.058) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| FBXO7 | SNV | Missense_Mutation | c.1118N>A | p.Arg373Lys | p.R373K | Q9Y3I1 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |